Abstract The objective of this study was to evaluate the expression of epithelial membrane protein-2 (EMP2) and its clinicopathological associations in patients with gallbladder carcinoma (GBC). A retrospective population-based cohort study was performed based on a biobank from 1986 to 2005. Biopsies of 164 GBC patients without initial distant metastasis were collected during surgical intervention. Immunoexpressions of EMP2 and Ki-67 were analyzed and the outcomes were correlated with clinicopathological features and patient survival. Results indicated that loss of EMP2 expression (50%) was correlated with female patients (p Z 0.037), advanced primary tumor (p < 0.017), vascular (p < 0.001), and perineural (p < 0.027) invasions and high Ki-67 labeling index (p < 0.001).In multivariate analysis, loss of EMP2 expression, high Ki-67 labeling index, and age emerged as independent prognosticators for worse diseasespecific (p < 0.001; p < 0.001; and p Z 0.001, respectively) and disease-free (p Z 0.002; p Z 0.002; and p Z 0.008, respectively) survivals, following by the American Joint Committee on Cancer stage (p < 0.001; p < 0.001; and p < 0.001, respectively). Collectively, loss of EMP2 expression is common and associated with adverse prognosticators and might confer tumor aggressiveness through hampering its interaction with specific membrane protein(s) and antiproliferative activity, and perhaps the downstream signal transduction pathway(s).
Introduction
Gallbladder carcinoma (GBC) is a rare malignant tumor and its etiology is poorly understood. The prevalence is variable globally, with higher occurrence in Asia, Latin America, and Eastern Europe. 1 Potential risk factors include age, gender, chronic inflammation, gallstones, infection, chemical pollutants, and gallbladder polyps. 2, 3 Tumor, node, and metastasis stage remain the best prognosticators for GBC at present. Surgical intervention is the only curative treatment option. An R0 resection (complete removal with microscopic examination of margins with no residual tumor) in subsequent re-exploration gives a better patient outcome. The median survival was 72 months for patient with GBC removed by simple cholecystectomy; however, this is significantly reduced to 12.7 months when microscopic or macroscopic residual disease was found after re-exploration. 4 The role of systemic treatment in GBC is still unclear, although a few retrospective or small Phase II studies show that GBC patients may benefit from adjuvant therapy. 5 Despite the improvement of the treatment modality, the prognosis of GBC remains dismal. The 5-year survival rate for GBC of each stage is about 5%. 6 Therefore, understanding the clinical and molecular mechanisms of GBC will provide a cornerstone in the development of early intervention, potential screening, and, above all, more effective treatment strategies. 3 Human epithelial membrane protein-2 gene (EMP2), mapped to chromosome 16, is highly conserved across vertebrates. 7e9 The expression pattern of EMP2 partially overlaps that of the peripheral myelin protein 22 transcript [PMP22, also known as the growth arrest-specific-3 (GAS3)]. By containing the claudin domain and sharing approximately 40% amino acid identity with PMP22/GAS3, 10 the EMP2 protein was detected as a novel member of this fourtransmembrane (tetraspan) superfamily. 11 In humans, EMP2 has a discrete cell type and tissue distribution, with high levels observed in the lung and moderate levels in the eye, heart, thyroid, uterus, and intestine. 10, 12, 13 Functionally, the best understood tetraspan proteins are connexins, which form the major structural element of gap junctions. Connexins play important roles in the regulation of cell growth and differentiation. Cancer cells usually have downregulated levels of gap junctions, and several lines of evidence suggest that loss of gap junctional intercellular communication is an important step in carcinogenesis. Re-expression of connexins in cancer cells causes normalization of cell growth control and reduced tumor growth. 
Immunohistochemical staining and assessment
Tissue section of 3 mm thickness were cut onto precoated slides from paraffin-embedded tissue blocks and were next routinely deparaffinized with xylene and rehydrated with ethanol washes. Slides were heated by microwave in a 10 mM citrate buffer (pH 6.0) for 7 minutes to retrieve antigens. Endogenous peroxidase was blocked with 3% H 2 O 2 . Slides were next washed by Tris-buffered saline for 15 minutes and subsequently incubated with a rabbit polyclonal primary antibody targeting EMP2 (Atlas Antibodies, Stockholm, Sweden) and Ki-67 (MIB-1; DAKO, Glostrup, Denmark) at dilutions of 1:75 and 1:100 for 1 hour, respectively. Primary antibodies were detected using the ChemMate EnVision Detection Kit (K5007; DAKO, Carpinteria, CA, USA). The slides were incubated and developed with the secondary antibody for 30 minutes and 3,3-diaminobenzidine for 5 minutes, followed by counterstained using Gill's hematoxylin. Incubation without the primary antibody was used a negative control. Immunoexpressions of EMP2 and Ki-67 were scored by two pathologists (Li C.F. and Huang H.Y.) using a multiheaded microscope to reach a consensus for each case without prior knowledge of clinical and follow-up information. Once !50% of tumor nuclei stained with Ki-67, was designated as high labeling index. Scoring of EMP2 immunoreactivity was evaluated based on a combination of both the percentage and intensity of positively stained tumoral membrane and cytoplasm to generate the H-score, which was calculated using the equation: H-score Z SP i (iþ1), where i was the intensity of stained tumor cells (0 to 4þ), and Pi was the percentage of stained tumor cells for each intensity varying from 0e100%. Tumors with H-score < median of all cases were regarded as EMP2 low expression.
Statistical analysis and follow-up
Statistics were performed using SPSS version 14.0 software (SPSS Inc., Chicago, IL, USA). Chi-square test and Wilcoxon test were used to compare the EMP2 expression level and Ki-67 labeling index, respectively, with various clinic Figure 1 Immunohistochemistry demonstrates that epithelial membrane protein-2 expression is (A) negative in nontumor epithelium; (B) variable in adenoma; (C) gradually decreases during transformation from adenoma (left, lower) to adenocarcinoma (right, upper); (D) strongly positive in well-differentiated, low-stage adenocarcinomas; (E) weakly positive in well-differentiated, high-stage adenocarcinoma; and (F) negative in poorly-differentiated, high-stage adenocarcinoma. opathological parameters. The end points analyzed were disease-specific survival (DSS) and disease-free survivals (DFS), calculated from the date of GBC surgical operation to the presence of disease-related mortality and tumor recurrence or systemic metastasis developed, respectively, or at the last follow-up appointment. The KaplaneMeier method and log-rank test were used to perform the univariate survival analyses and to evaluate the prognostic differences between groups. Parameters with p < 0.05 in univariate analysis were subsequently included into the multivariate assay with the Cox proportional hazard model. For all analyses, two-sided tests of significance were used with p < 0.05 considered significant.
Results

Clinicopathological features
The clinicopathological characters of GBC patients in this study are listed in Table 1 . Most patients were female and aged >60 years. Around 80% of the patients with tumors extend beyond muscle layer (T2 or above) during diagnosis.
Histologically, 135 tumors exhibit tubular arrangement and 17 tumors display papillary growth pattern. Other histological subtypes were also identified with low percentages, including adenosquamous (n Z 5; 3%), undifferentiated (n Z 4; 2.4%), signet-ring cell (n Z 2; 1.2%), and clear cell (n Z1; 0.6%) carcinomas. The histological grading of the tumors included 65 Grade 1, 69 Grade 2, 26 Grade 3, and four Grade 4 tumors. Vascular and perineuralinvasions were observed in 106 cases and 140 cases, respectively. Tumor necrosis was seen in 87 events.
Correlations of EMP2 immunoexpression with clinicopathologic variables and proliferative index
As shown in Fig. 1, EMP2 protein expression was identified in both cytoplasm and membrane. In gall bladder tissues, EMP2 proteins were not expressed in the nontumor epithelium (Fig. 1A ), but were inconsistently but positively expressed in the adenoma. During transformation from adenoma (left, bottom; Fig. 1C ) to adenocarcinoma (right, upper; Fig. 1C) , the EMP2 protein level gradually decreases. Intriguingly, prominent EMP2 cytoplasmic and membrane expressions were observed in well-differentiated, low-stage adenocarcinomas (Fig. 1D) . In well-differentiated/high-stage and poorlydifferentiated/high-stage adenocarcinomas, EMP2 are weakly and not expressed, respectively. After dichotomizing the tumors into EMP2 high and low expressions, as demonstrated in Table 2 , low EMP2 protein levels correlated with gender (p < 0.037), advanced primary tumor (pT; p < 0.017), absence of vascular (p < 0.001) and perineural (p < 0.027) invasions, and high Ki-67 labeling index (p < 0.001).
Clinical outcomes
The correlations of clinical outcomes with various clinicopathological factors and EMP2 protein level as well as Ki-67 labeling index are shown in Table 3 . As shown in Fig. 2 , follow-up for some patients have extended to 240 months;
however, most patients were subjected to rapid disease relapse. Therefore, the median follow-up duration did not reach 240 months. Poor DSS and DFS were associated with older patients (p Z 0.0017; p Z 0.0090), advanced pT (p Z 0.0001; p < 0.0001) and AJCC (p < 0.0001; p < 0.0001; Fig. 2A and B) stages, vascular invasion (p < 0.0001; p < 0.0001), low EMP2 level (p < 0.0001; p < 0.0001; Fig. 2C and D) and high Ki-67 labeling index (p < 0.0001; p Z 0.0002; Fig. 2E and F 
Discussion
In the present study, we found that loss of EMP2 immunostaining is one independent and potent prognosticator for both DSS and DFS in a subset of patients with GBC, similar to our previous study in the nasopharyngeal carcinoma. 16 Instead, significantly high EMP2 expression was found in ovarian cancer through activation of caveolins/glycosylphosphatidyl inositol-linked proteins, 17 and was identified as an early predictor of endometrial cancers with unfavorable outcome. 18 Due to non-neoplastic peritoneal, surface tissues were complete negative for EMP2 staining; thus EMP2 Figure 2 KaplaneMeier plotting illustrates the prognostic significance of tumor stage for: (A) disease-specific survival, and (B) disease-free survival, respectively. The predictive values of (C, D) epithelial membrane protein-2 (EMP2) and (E, F) Ki-67 are also demonstrated. Exp. Z expression.
was regarded as increased expression in tumor cells in ovarian cancer. 19 Moderately intensive diffuse immunohistochemical staining of tumor cell cytoplasm were identified in endometrioid adenocarcinoma, serous carcinoma, mixed endometrioid, and clear cell carcinoma. 20 However, compared to undifferentiated ones, EMP2 is strongly expressed in squamous metaplasia of nasopharyngeal epithelium; loss of EMP2 expression was identified in advanced TNM stages and confers an independent prognosticator in nasopharyngeal carcinomas. 16 Along with the expression pattern of EMP2 in patients with GBC, we suggest that EMP2 might play distinct roles in different organs through interaction with various membrane proteins in tissue-and time-specific manners.
These aspects are reflected in several studies. For example, surface expression of the a6b1 integrin was specifically increased by EMP2 in NIH3T3 fibroblasts. 21 Moreover, surface expression and trafficking of integrin a5b3 during the window of implantation, which are essential for endometrial-blastocyst interaction in mice, were affected by the EMP2 level and the association between EMP2 and focal adhesion kinase. 18, 22, 23 In mammals, 18 a and 8 b subunits assemble into 24 different integrins, which bind collagens, laminins, or arginineeglycineeaspartic acidcontaining proteins. Integrins are regulated by conformational changes, clustering, and trafficking and regulatory mechanisms differ strongly between individual integrins and between cell types. Defective integrin activation or integrin signaling is associated with an array of pathological conditions. 24 Endocytosis and recycling are crucial in the regulation of integrin turnover and redistribution in adherent cells, especially during dynamic processes such as migration and invasion. 25 Therefore, EMP2 probably plays a tumor suppressor role through interacting with specific integrin(s) in epithelial cells, and thereafter, manages regular signaling transduction in benign conditions. A high labeling index of Ki-67 also independently portends worse DSS and DFS. The expression of Ki-67 protein is strictly associated with cell proliferation. 26 A significant inverse correlation between EMP2 protein level and Ki-67 labeling index additionally infers that EMP2 might embrace antiproliferative activity. Indeed, during the multistep development of human tumors, several biological capabilities are acquired, including the sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. 27 Regarding evading growth suppressors, one study that applied the suppression subtractive hybridization technology isolated mouse ortholog Emp2, which suppresses B cell lymphoma tumorigenicity through a functional tumor suppressor phenotype in vitro and in vivo.
8 Likewise, the susceptibility to allogeneic cytotoxic T lymphocytes of a mouse malignant, Emp2-deficient cell line (MV) 8 has been enhanced by retroviral overexpression of Emp2 gene. 28 In addition, constitutive overexpression of EMP2 or other epithelial membrane proteins including EMP1, EMP3, and PMP22, in human HEK293 epithelial cells, leading to the development of apoptotic phenotypes, were demonstrated by purinergic receptor P2X, ligand-gated ion channel, 7 (P2RX7)-mediated cell blebbing, annexin V binding to plasma membrane, and cell death, through a caspasedependent pathway. Physically, the C-terminal domain of P2RX7 protein associates with EMPs and mediates some aspects of the downstream signaling following P2RX7 activation. 29 All these studies support our clinical observations, reinforcing that EMP2 might play distinct characteristics in different cellular contexts. In multivariate analyses, except for EMP2 and Ki-67 protein levels, both higher AJCC stage (II-IV) and age (!70 years) contribute to the increased HRs of DSS and DFS in patients with GBC. Stage is the most important factor in the survival, management, and prognosis of GBC patients as well as in those with other carcinomas. 4 These findings are consistent with the result from another cohort, 30 as well as the fact that carcinogenesis is an age-dependent process.
We further identified that EMP2 protein is negative in nontumor epithelium, and variable but positive in adenoma of the gallbladder, but gradually lost during transformation to adenocarcinoma. As mentioned in the literature, GBC can arise from either a pathway involving metaplasia or dysplasia or one in which there is a pre-existing adenoma. 31 A two-step model might explain our observations, i.e., oncogenes initiate gallbladder adenoma formation and those patients with upregulations of EMP2 protein present well differentiated, less aggressive, and better outcomes. Loss of EMP2 expression, therefore, may serve as a molecular indicator leading to neoplastic transformation as well as poor differentiation in GBC patients. Along with significant correlations between loss of EMP2 expression and advanced primary tumor, vascular, and perineural invasions and Ki-67 labeling index in patients with GBC, we consequently, advocate its prospective role in preventing GBC progression and aggressiveness. Although the exact characteristics of the EMP2 protein in GBC development remain to be elucidated, the potential utility of EMP2 immunostaining as a prognostic biomarker in GBCs is assured.
In conclusion, loss of EMP2 expression is common and associated with adverse prognosticators and might confer tumor aggressiveness through impeding its interaction with specific membrane protein(s) and antiproliferative activity, and probably the downstream signal transduction pathway(s).
